Deutsch
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
oligosaccharide/entzündung
Der Link wird in der Zwischenablage gespeichert
Seite 1 von 57 Ergebnisse
Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin C and anti-inflammatory agents
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
FIELD OF THE DISCLOSURE
The present disclosure relates to human milk oligosaccharides (HMOs) for modulating inflammation in an infant, toddler, or child. More particularly, the present disclosure relates to human milk fortifiers, preterm and term infant formulas and pediatric formulas comprising
Inhibiting inflammation with milk oligosaccharides
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND OF THE INVENTION
Various components in human milk, e.g., milk immunoglobulins, leukocytes, oligosaccharides, and glycoconjugates, protect infants against infectious diseases. Human milk is thus considered a natural efficacious "nutriceutical," i.e., a model food that conveys immunologic
Inhibiting inflammation with milk oligosaccharides
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND OF THE INVENTION
Various components in human milk, e.g., milk immunoglobulins, leukocytes, oligosaccharides, and glycoconjugates, protect infants against infectious diseases. Human milk is thus considered a natural efficacious "nutriceutical," i.e., a model food that conveys immunologic
Human milk oligosaccharides for modulating inflammation
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
FIELD OF THE DISCLOSURE
The present disclosure relates to human milk oligosaccharides (HMOs) for modulating inflammation in an infant, toddler, or child. More particularly, the present disclosure relates to human milk fortifiers, preterm and term infant formulas and pediatric formulas comprising
Human milk oligosaccharides for modulating inflammation
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
FIELD OF THE DISCLOSURE
The present disclosure relates to human milk oligosaccharides (HMOs) for modulating inflammation in an infant, toddler, or child. More particularly, the present disclosure relates to human milk fortifiers, preterm and term infant formulas and pediatric formulas comprising
Nutritional formulations using human milk oligosaccharides for modulating inflammation
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
FIELD OF THE DISCLOSURE
The present disclosure relates to a nutritional composition for use in modulating or reducing inflammation in an adult or elderly individual in need thereof. More particularly, in some aspects, the nutritional composition reduces inflammation and the incidence of inflammatory
Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is directed to methods for reducing the degree of inflammation arising from a secondary immune response in a mammal due to antigen exposure (challenge) by the time dependent administration of an oligosaccharide glycoside related to
Preparation and use of sulfated oligosaccharides
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
FIELD OF THE INVENTION
This invention relates to sulfated oligosaccharides, their preparation and use as anti-angiogenic, anti-metastatic and/or anti-inflammatory agents.
BACKGROUND TO THE INVENTION
Heparan sulfates belong to the glycosaminoglycan family of polysaccharides. They are present in most
Keratan sulfate oligosaccharide fraction and pharmaceutical containing the same
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
TECHNICAL FIELD
The present invention relates to an anti-inflammatory agent, antiallergic agent, immunomodulator, cell differentiation inducer, apoptosis inducer, and a keratan sulfate oligosaccharide which is useful as an active ingredient of these pharmaceuticals.
BACKGROUND ART
Keratan sulfate is
Keratan sulfate oligosaccharide fraction and pharmaceutical containing the same
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
TECHNICAL FIELD
The present invention relates to an anti-inflammatory agent, antiallergic agent, immunomodulator, cell differentiation inducer, apoptosis inducer, and a keratan sulfate oligosaccharide which is useful as an active ingredient of these pharmaceuticals.
BACKGROUND ART
Keratan sulfate is
Inflammation imaging and therapy
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
FIELD OF THE INVENTION
This invention relates to imaging agents which comprise a conjugate of an oligosaccharide with an imaging moiety. The agents of the invention can be used in a variety of imaging techniques including magnetic resonance imaging, positron emission tomography (PET),
Radiolabeled glucans which bind to leukocytes, sites of infection, inflammation, atherosclerosis, or cancer
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to radiodiagnostic agents and reagents for preparing such agents, and also methods for producing radiolabeled radiodiagnostic agents. Specifically, the invention relates to technetium-99m (.sup.99m Tc) labeled agents,
Galactosylated pro-drugs of non-steroidal anti-inflammatories with improved pharmacokinetic characteristics and reduced toxicity of the starting drug
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
The present invention relates to galactosylated pro-drugs of non-steroidal anti-inflammatories with free acid function and the process of synthesis thereof, which enables minimization of the gastrointestinal toxicity of the starting anti-inflammatory by means of esterification of its carboxylic
Disaccharide inflammation inhibitors and uses thereof
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to the fields of inflammation and carbohydrate and glycoprotein chemistry. More specifically, the present invention relates to novel disaccharide inhibitors of inflammation.
2. Description of the Related
Methods for the prevention or treatment of inflammatory bowel diseases
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
TECHNICAL FIELD
This invention relates to a novel preventive and curative agent for inflammatory bowel diseases. More particularly, this invention relates to a preventive and curative agent for inflammatory bowel diseases, using a water-soluble chromanol glucoside as an active ingredient.
BACKGROUND
Die vollständigste Datenbank für Heilkräuter, die von der Wissenschaft unterstützt wird
- Arbeitet in 55 Sprachen
- Von der Wissenschaft unterstützte Kräuterkuren
- Kräutererkennung durch Bild
- Interaktive GPS-Karte - Kräuter vor Ort markieren (in Kürze)
- Lesen Sie wissenschaftliche Veröffentlichungen zu Ihrer Suche
- Suchen Sie nach Heilkräutern nach ihrer Wirkung
- Organisieren Sie Ihre Interessen und bleiben Sie über Neuigkeiten, klinische Studien und Patente auf dem Laufenden
Geben Sie ein Symptom oder eine Krankheit ein und lesen Sie über Kräuter, die helfen könnten, geben Sie ein Kraut ein und sehen Sie Krankheiten und Symptome, gegen die es angewendet wird.
* Alle Informationen basieren auf veröffentlichten wissenschaftlichen Forschungsergebnissen
